Dose Response Effects of Inhaled Fluticasone on Airway Effects of Hypertonic-Saline in Asthma
Information source: National Heart, Lung, and Blood Institute (NHLBI)
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Asthma
Intervention: Fluticasone (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: National Heart, Lung, and Blood Institute (NHLBI)
Summary
This study investigates the effect of a inhaled corticosteroid (fluticasone or "Flovent") on
airway narrowing induced by hypertonic saline (salty water). The study hypothesis is that
fluticasone will be more effective in preventing saline-induced airway narrowing than
methacholine-induced narrowing.
Clinical Details
Official title: A Randomized Double Blind Study of the Dose Response Effects of Fluticasone Propionate on Hypertonic-Saline Induced Bronchoconstriction in Asthmatic Subjects
Study design: Basic Science, Randomized, Double Blind (Subject, Investigator), Dose Comparison, Parallel Assignment, Efficacy Study
Primary outcome: FEV1
Secondary outcome: PC20 methacholine
Eligibility
Minimum age: 18 Years.
Maximum age: 75 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Clinical diagnosis of asthma
Exclusion Criteria:
- Habitual cigarette smoking
Locations and Contacts
University of California, San Francisco, San Francisco, California 94143, United States
Additional Information
Starting date: January 2000
Ending date: December 2007
Last updated: January 21, 2008
|
